Premium
Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide
Author(s) -
Grunberger G.,
Forst T.,
Fernández Landó L.,
Pechtner V.,
Shaginian R.,
Jia N.,
Gough S.
Publication year - 2016
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/dme.12833
Subject(s) - medicine , dulaglutide , diabetes mellitus , endocrinology , type 2 diabetes , exenatide
Aims To assess whether early measures of fasting blood glucose predict later glycaemic response with once‐weekly dulaglutide in patients with Type 2 diabetes mellitus. Methods Post hoc analyses were conducted separately for two phase 3 studies ( AWARD –5 and AWARD –1) in patients assigned to once‐weekly dulaglutide. Week 2 fasting blood glucose was used as a predictor variable, and glycaemic treatment response was defined by HbA 1c response based on a composite efficacy endpoint. The association between fasting blood glucose and the glycaemic response was analysed using chi‐square tests. Results There was a strong association between fasting blood glucose < 7.9 mmol/l at week 2 and achieving the HbA 1c composite efficacy endpoint at week 26 ( P < 0.01). Higher fasting blood glucose at week 2, however, did not predict absence of glycaemic response and requires further assessment. Conclusions Fasting blood glucose measured at 2 weeks may be an early and useful predictor of glycaemic response to once‐weekly dulaglutide treatment.